Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 7/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7107413 | 0.86 | MC4R (0.37) | — | |
| SCHEMBL10289745 | 0.81 | ESR2 (0.53) | SCN9AMAPK1MAPTESR2UCHL1 | |
| SCHEMBL29554603 | 0.80 | UCHL1 (0.53) | P2RX3SCN9AMAPK1MAPTESR2 | |
| SCHEMBL5774734 | 0.80 | UCHL1 (0.53) | P2RX3SCN9AMAPK1MAPTESR2 | |
| SCHEMBL5778372 | 0.79 | ESR2 (0.51) | P2RX3SCN9AMAPK1MAPTESR2 | |
| SCHEMBL29421814 | 0.79 | ESR2 (0.51) | P2RX3SCN9AMAPK1MAPTESR2 | |
| SCHEMBL22530017 | 0.79 | ESR2 (0.51) | P2RX3SCN9AMAPK1MAPTESR2 | |
| SCHEMBL17687053 | 0.79 | NR1H2 (0.53) | SCN9AMAPK1MAPTESR2UCHL1 | |
| SCHEMBL30606082 | 0.79 | NR1H2 (0.53) | SCN9AMAPK1MAPTESR2UCHL1 | |
| SCHEMBL5776971 | 0.78 | ESR2 (0.50) | SCN9AMAPK1MAPTESR2UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483257-B1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-09-13 | — | — | EP | disclosed |
| US-6936619-B2 | Cardiovascular disorders; antilipemic agents; sexual disorders | PFIZER, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040029859-A1 | Compounds useful in therapy | PFIZER INC. | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029859-A1 | Compounds useful in therapy | ADRA1D, HSD3B1, PTGER1 | P2RX3 2301/4885SCN9A 744/4885MAPK1 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.